NASDAQ:ZIOP - Ziopharm Oncology Stock Price, Price Target & More

$4.30 +0.02 (+0.47 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$4.28

Today's Range$4.24 - $4.37

52-Week Range$3.33 - $7.88

Volume515,536 shs

Average Volume1.59 million shs

Market Capitalization$636.52 million

P/E Ratio-8.17

Dividend YieldN/A

Beta1.72

About Ziopharm Oncology (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, a gene therapy product candidate to treat patients with recurrent glioblastoma. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has collaboration agreements with Precigen, Inc., MD Anderson Cancer Center, the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.

Receive ZIOP News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:ZIOP

CUSIP98973P10

Webwww.ziopharm.com

Phone617-259-1970

Debt

Debt-to-Equity RatioN/A

Current Ratio4.35%

Quick Ratio4.35%

Price-To-Earnings

Trailing P/E Ratio-8.17

Forward P/E Ratio-8.11

P/E GrowthN/A

Sales & Book Value

Annual Sales$6.39 million

Price / Sales95.82

Cash FlowN/A

Price / CashN/A

Book Value($0.68) per share

Price / Book-6.32

Profitability

EPS (Most Recent Fiscal Year)($0.53)

Net Income$-54,320,000.00

Net Margins-928.50%

Return on EquityN/A

Return on Assets-53.51%

Miscellaneous

Employees46

Outstanding Shares142,400,000

How to Become a New Pot Stock Millionaire

Ziopharm Oncology (NASDAQ:ZIOP) Frequently Asked Questions

What is Ziopharm Oncology's stock symbol?

Ziopharm Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

How were Ziopharm Oncology's earnings last quarter?

Ziopharm Oncology Inc (NASDAQ:ZIOP) issued its quarterly earnings results on Thursday, March, 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.13). The biotechnology company had revenue of $1.60 million for the quarter, compared to analysts' expectations of $1.59 million. Ziopharm Oncology's revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.11) EPS. View Ziopharm Oncology's Earnings History.

When is Ziopharm Oncology's next earnings date?

Ziopharm Oncology is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Ziopharm Oncology.

What price target have analysts set for ZIOP?

2 brokerages have issued 12-month target prices for Ziopharm Oncology's stock. Their predictions range from $10.00 to $10.00. On average, they anticipate Ziopharm Oncology's stock price to reach $10.00 in the next twelve months. View Analyst Ratings for Ziopharm Oncology.

Are investors shorting Ziopharm Oncology?

Ziopharm Oncology saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 35,871,152 shares, an increase of 1.4% from the March 15th total of 35,375,906 shares. Based on an average trading volume of 1,008,435 shares, the days-to-cover ratio is presently 35.6 days. Currently, 28.2% of the company's shares are short sold.

Who are some of Ziopharm Oncology's key competitors?

Some companies that are related to Ziopharm Oncology include TherapeuticsMD (TXMD), G1 Therapeutics (GTHX), Theravance Biopharma (TBPH), Revance Therapeutics (RVNC), Dynavax Technologies (DVAX), Mallinckrodt (MNK), WAVE Life Sciences (WVE), PTC Therapeutics (PTCT), Epizyme (EPZM), Athenex (ATNX), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX), CytomX Therapeutics (CTMX), Retrophin (RTRX), Zai Lab (ZLAB), MacroGenics (MGNX), Uniqure (QURE) and Biohaven Pharmaceutical (BHVN).

Who are Ziopharm Oncology's key executives?

Ziopharm Oncology's management team includes the folowing people:

Dr. Laurence James Neil Cooper Ph.D., M.D., Chief Exec. Officer (Age 53)
Mr. Kevin G. Lafond, Sr. VP of Fin., CFO, Chief Accounting Officer, Treasurer & Corp. Controller (Age 62)
Dr. Francois Lebel M.D., Chief Medical Officer and Exec. VP of R&D (Age 66)
Dr. David M. Mauney M.D., Exec. VP, Chief Bus. Officer & Interim COO (Age 49)
Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.

Has Ziopharm Oncology been receiving favorable news coverage?

Media headlines about ZIOP stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ziopharm Oncology earned a coverage optimism score of 0.22 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.94 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Ziopharm Oncology?

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ziopharm Oncology's stock price today?

One share of ZIOP stock can currently be purchased for approximately $4.29.

How big of a company is Ziopharm Oncology?

Ziopharm Oncology has a market capitalization of $636.52 million and generates $6.39 million in revenue each year. The biotechnology company earns $-54,320,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. Ziopharm Oncology employs 46 workers across the globe.

How can I contact Ziopharm Oncology?

Ziopharm Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34 NAVY YARD PLAZA, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]

MarketBeat Community Rating for Ziopharm Oncology (ZIOP)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		205 (Vote Outperform)
Underperform Votes:		243 (Vote Underperform)
Total Votes:		448

MarketBeat's community ratings are surveys of what our community members think about Ziopharm Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Ziopharm Oncology (NASDAQ:ZIOP) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

2 Wall Street analysts have issued ratings and price targets for Ziopharm Oncology in the last 12 months. Their average twelve-month price target is $10.00, suggesting that the stock has a possible upside of 132.56%. The high price target for ZIOP is $10.00 and the low price target for ZIOP is $10.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.50	2.50	2.67	2.67
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$10.00	$10.00	$16.50	$16.50
Price Target Upside:	132.56% upside	147.52% upside	271.62% upside	198.37% upside

Ziopharm Oncology (NASDAQ:ZIOP) Consensus Price Target History

Price Target History for Ziopharm Oncology (NASDAQ:ZIOP)

Ziopharm Oncology (NASDAQ:ZIOP) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/5/2018	HC Wainwright	Set Price Target	Buy	$10.00	High
12/11/2017	Raymond James	Reiterated Rating	Hold		High
2/28/2017	Griffin Securities	Reiterated Rating	Buy	$23.00	N/A
1/12/2017	JPMorgan Chase	Reiterated Rating	Hold		N/A
8/10/2016	Wells Fargo	Upgrade	Underperform -> Market Perform		N/A
7/18/2016	Mizuho	Reiterated Rating	Neutral	$7.00 -> $5.00	N/A

(Data available from 4/20/2016 forward)

Ziopharm Oncology (NASDAQ:ZIOP) Earnings History and Estimates Chart

Earnings by Quarter for Ziopharm Oncology (NASDAQ:ZIOP)

Ziopharm Oncology (NASDAQ:ZIOP) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.53 EPS
Next Year EPS Consensus Estimate: $-0.52 EPS

Ziopharm Oncology (NASDAQ ZIOP) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018
3/1/2018	Q4 2017	($0.13)	($0.13)	$1.59 million	$1.60 million	View	Listen
11/6/2017	Q3 2017	($0.13)	($0.13)	$1.66 million	$1.60 million	View	N/A
7/31/2017	Q2 2017	($0.13)	($0.13)	$1.66 million	$1.60 million	View	N/A
5/1/2017	Q1 2017	($0.12)	($0.15)	$1.71 million	$1.60 million	View	Listen
2/16/2017	Q4 2016	($0.11)	($0.11)	$1.62 million	$1.60 million	View	N/A
11/9/2016	Q3 2016	($0.11)	($0.11)	$1.45 million	$1.60 million	View	N/A
8/9/2016	Q216	($0.11)	($1.01)	$1.52 million	$1.70 million	View	N/A
5/10/2016	Q1	($0.08)	($0.09)	$1.89 million	$1.97 million	View	N/A
2/24/2016	Q4	($0.07)	($0.07)	$1.82 million	$1.92 million	View	N/A
11/2/2015	Q315	($0.13)	($0.14)	$1.19 million	$1.90 million	View	N/A
8/10/2015	Q2	($0.22)	($0.11)	$57.70 million	$0.27 million	View	N/A
5/7/2015		($0.13)	($0.10)	$0.20 million	$0.30 million	View	N/A
2/26/2015	Q414	($0.14)	($0.09)	$420.00 million	$0.34 million	View	N/A
10/30/2014	Q314	($0.12)	($0.06)	$0.20 million	$0.63 million	View	N/A
8/7/2014	Q214	($0.17)	($0.06)	$7.50 million	$0.20 million	View	N/A
5/8/2014	Q114	($0.10)	($0.10)	$0.20 million	$0.20 million	View	N/A
3/3/2014	Q413	($0.15)	($0.09)	$0.20 million	$0.20 million	View	N/A
10/22/2013	Q313	($0.17)	($0.20)		$0.20 million	View	N/A
8/8/2013	Q2 2013	($0.24)	($0.22)	$0.20 million	$0.20 million	View	N/A
5/7/2013	Q1 2013	($0.28)	($0.28)	$0.20 million	$0.20 million	View	N/A
3/18/2013	Q4 2012	($0.29)	($0.48)	$0.17 million	$0.20 million	View	N/A
11/8/2012	Q312	($0.28)	($0.28)	$0.20 million	$0.20 million	View	N/A
8/2/2012		($0.23)	($0.29)			View	N/A
5/3/2012		($0.22)	($0.25)			View	N/A
2/29/2012		($0.23)	($0.24)			View	N/A
11/3/2011		($0.28)	($0.01)			View	N/A
8/1/2011		($0.23)	($0.16)			View	N/A
5/5/2011	Q1 2011	($0.17)	($0.18)			View	N/A
3/1/2011	Q4 2010	($0.25)	($0.25)			View	N/A
11/4/2010	Q3 2010	($0.17)	($0.18)			View	N/A
7/30/2010	Q2 2010	($0.13)	$0.19			View	N/A
4/30/2010	Q1 2010	($0.10)	($0.11)			View	N/A
3/18/2010	Q4 2009	($0.12)	$0.03			View	N/A
11/11/2009	Q3 2009		($0.13)			View	N/A
8/14/2009	Q2 2009		($0.10)			View	N/A
5/15/2009	Q1 2009		($0.16)			View	N/A
3/24/2009	Q4 2008	($0.19)	($0.21)			View	N/A
10/30/2008	Q3 2008	($0.23)	($0.26)			View	N/A
7/31/2008	Q2 2008	($0.36)	($0.31)			View	N/A
5/12/2008	Q1 2008	($0.35)	($0.41)			View	N/A
2/22/2008	Q4 2007	($0.39)	($0.36)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Ziopharm Oncology (NASDAQ:ZIOP) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Ziopharm Oncology (NASDAQ ZIOP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 40.15%

Insider Trading History for Ziopharm Oncology (NASDAQ:ZIOP)

Institutional Ownership by Quarter for Ziopharm Oncology (NASDAQ:ZIOP)

Ziopharm Oncology (NASDAQ ZIOP) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/8/2017	David M Md Mauney	EVP	Buy	4,270	$4.68	$19,983.60	58,662
11/8/2017	Laurence James Neil Cooper	CEO	Buy	6,440	$4.68	$30,139.20	1,083,731
6/4/2015	Murray Brennan	Director	Sell	40,000	$9.70	$388,000.00
2/9/2015	Randal J Kirk	Director	Buy	1,440,000	$8.75	$12,600,000.00
10/29/2013	Randal J Kirk	Director	Buy	2,857,143	$3.50	$10,000,000.50

(Data available from 1/1/2013 forward)

Ziopharm Oncology (NASDAQ ZIOP) News Headlines

Source:

Date	Headline
	Ziopharm Oncology (ZIOP) Lowered to "Sell" at BidaskClub www.americanbankingnews.com - April 19 at 10:42 AM
	Brokerages Anticipate Ziopharm Oncology Inc (ZIOP) Will Announce Quarterly Sales of $1.55 Million www.americanbankingnews.com - April 19 at 2:28 AM
	Ziopharm Oncology (ZIOP) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - April 17 at 10:21 PM
	-$0.13 EPS Expected for Ziopharm Oncology Inc (ZIOP) This Quarter www.americanbankingnews.com - April 17 at 7:27 PM
	Ziopharm Oncology (ZIOP) Given a $10.00 Price Target at HC Wainwright www.americanbankingnews.com - April 14 at 3:36 PM
	Ziopharm Oncology (ZIOP) Raised to Hold at BidaskClub www.americanbankingnews.com - April 13 at 9:39 AM
	Ziopharm Oncology (ZIOP) Downgraded by ValuEngine to Sell www.americanbankingnews.com - April 10 at 4:28 PM
	Ziopharm Oncology (ZIOP) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - April 5 at 12:30 AM
	Global Melanoma Therapeutics Market Opportunities 2018: AstraZeneca, Novartis AG, Ziopharm Oncology, Celgene Corporation www.marketwatch.com - April 4 at 5:22 PM
	ZIOPHARM Oncology Inc. (ZIOP) Expected to Post Quarterly Sales of $1.55 Million www.americanbankingnews.com - April 2 at 2:12 AM
	Edited Transcript of ZIOP earnings conference call or presentation 1-Mar-18 9:30pm GMT finance.yahoo.com - April 1 at 9:51 AM
	Zacks: Analysts Expect ZIOPHARM Oncology Inc. (ZIOP) Will Post Earnings of -$0.13 Per Share www.americanbankingnews.com - March 31 at 7:12 PM
	ZIOPHARM Oncology (ZIOP) Rating Increased to Sell at BidaskClub www.americanbankingnews.com - March 30 at 5:08 PM
	Financial Analysis: ZIOPHARM Oncology (ZIOP) vs. Immune Design (IMDZ) www.americanbankingnews.com - March 23 at 7:08 PM
	ZIOPHARM Oncology Inc. (ZIOP) Expected to Announce Quarterly Sales of $1.53 Million www.americanbankingnews.com - March 16 at 3:44 AM
	Zacks Investment Research Downgrades ZIOPHARM Oncology (ZIOP) to Sell www.americanbankingnews.com - March 15 at 12:50 PM
	-$0.13 EPS Expected for ZIOPHARM Oncology Inc. (ZIOP) This Quarter www.americanbankingnews.com - March 14 at 5:24 PM
	Short Interest in ZIOPHARM Oncology Inc. (ZIOP) Declines By 3.7% www.americanbankingnews.com - March 12 at 2:14 AM
	ZIOPHARM Oncology (ZIOP) Raised to "Hold" at Zacks Investment Research www.americanbankingnews.com - March 9 at 9:02 PM
	ZIOPHARM Oncology, Inc. 2017 Q4 - Results - Earnings Call Slides seekingalpha.com - March 5 at 4:25 PM
	ZIOPHARM Oncology (ZIOP) Earns Buy Rating from HC Wainwright www.americanbankingnews.com - March 5 at 11:48 AM
	ZIOPHARM Oncology (ZIOP) Rating Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - March 3 at 12:00 PM
	Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat finance.yahoo.com - March 2 at 4:13 PM
	ZIOPHARM Oncology (ZIOP) Downgraded to "Strong Sell" at ValuEngine www.americanbankingnews.com - March 1 at 11:30 PM
	ZIOPHARM Oncology (ZIOP) Announces Earnings Results www.americanbankingnews.com - March 1 at 9:12 PM
	Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update finance.yahoo.com - March 1 at 4:19 PM
	ZIOPHARM Oncology Inc. (ZIOP) Sees Large Growth in Short Interest www.americanbankingnews.com - March 1 at 2:40 AM
	ZIOPHARM Oncology Inc. (ZIOP) Expected to Post Quarterly Sales of $1.59 Million www.americanbankingnews.com - February 27 at 4:16 AM
	Brokerages Expect ZIOPHARM Oncology Inc. (ZIOP) to Announce -$0.13 EPS www.americanbankingnews.com - February 25 at 5:17 PM
	ZIOPHARM Oncology (ZIOP) Set to Announce Quarterly Earnings on Thursday www.americanbankingnews.com - February 22 at 2:32 AM
	ZIOPHARM Oncology Inc. (ZIOP) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - February 18 at 1:30 AM
	Wired News – Ziopharm Oncology Presents Data on Rapid Production of CAR T Cells at Keystone Symposia finance.yahoo.com - February 14 at 3:23 PM
	Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference ... - GlobeNewswire (press release) globenewswire.com - February 13 at 3:21 PM
	Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1 finance.yahoo.com - February 13 at 3:21 PM
	Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular ... - GlobeNewswire (press release) globenewswire.com - February 13 at 6:14 AM
	Pre-Open Movers 02/12: (CSRA) (HGSH) (COLL) Higher; (AXON) (SPNS) (LJPC) Lower (more...) www.streetinsider.com - February 12 at 3:21 PM
	ZIOPHARM Oncology Inc. (ZIOP) Expected to Announce Quarterly Sales of $1.59 Million www.americanbankingnews.com - February 11 at 6:50 AM
	ZIOPHARM Oncology Inc. (ZIOP) Short Interest Down 5.9% in January www.americanbankingnews.com - February 10 at 1:40 AM
	Ziopharm stock rallies after company says nothing to see here, folks - MarketWatch www.marketwatch.com - February 7 at 6:10 AM
	Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance finance.yahoo.com - February 6 at 3:21 PM
	Ziopharm stock rallies after company says nothing to see here, folks finance.yahoo.com - February 6 at 3:21 PM
	Technical Perspectives on Biotech Stocks -- Vericel, Viking Therapeutics, VistaGen Therapeutics, and ZIOPHARM ... - PR Newswire (press release) www.prnewswire.com - February 2 at 3:22 PM
	ZIOPHARM Oncology Inc. (ZIOP) Receives Average Recommendation of "Hold" from Analysts www.americanbankingnews.com - January 24 at 1:44 AM
	Did ZIOPHARM Oncology Inc’s (NASDAQ:ZIOP) Earnings Growth Outperform The Industry? finance.yahoo.com - January 23 at 9:32 AM
	Today’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and ZIOPHARM Oncology finance.yahoo.com - January 23 at 9:32 AM
	Reviewing Allena Pharmaceuticals (ALNA) & ZIOPHARM Oncology (ZIOP) www.americanbankingnews.com - January 23 at 1:18 AM
	Zacks: Brokerages Anticipate ZIOPHARM Oncology Inc. (ZIOP) to Announce -$0.13 Earnings Per Share www.americanbankingnews.com - January 23 at 1:18 AM
	ZIOPHARM Oncology (ZIOP) Stock Rating Reaffirmed by Zacks Investment Research www.americanbankingnews.com - January 13 at 4:08 PM
	BidaskClub Downgrades ZIOPHARM Oncology (ZIOP) to Strong Sell www.americanbankingnews.com - January 12 at 12:40 AM
	Active-Investors: Blog Exposure - ZIOPHARM Updated on Key Clinical Programs and Corporate Development Activities www.finanznachrichten.de - January 11 at 11:00 AM

Ziopharm Oncology (NASDAQ:ZIOP) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Ziopharm Oncology (NASDAQ:ZIOP) Income Statement, Balance Sheet and Cash Flow Statement

Ziopharm Oncology (NASDAQ ZIOP) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff